Insider Selling: Hims & Hers Health, Inc. (NYSE:HIMS) Insider Sells 2,503 Shares of Stock

Hims & Hers Health, Inc. (NYSE:HIMS - Get Free Report) insider Soleil Boughton sold 2,503 shares of the stock in a transaction dated Monday, April 15th. The shares were sold at an average price of $13.95, for a total transaction of $34,916.85. Following the completion of the sale, the insider now directly owns 164,363 shares in the company, valued at $2,292,863.85. The sale was disclosed in a filing with the SEC, which is available at this hyperlink.

Soleil Boughton also recently made the following trade(s):

• On Monday, April 1st, Soleil Boughton sold 2,503 shares of Hims & Hers Health stock. The shares were sold at an average price of $15.65, for a total transaction of $39,171.95.
• On Wednesday, March 13th, Soleil Boughton sold 63,621 shares of Hims & Hers Health stock. The shares were sold at an average price of $15.17, for a total transaction of $965,130.57.
• On Friday, February 9th, Soleil Boughton sold 4,080 shares of Hims & Hers Health stock. The shares were sold at an average price of $10.03, for a total transaction of $40,922.40.
• On Monday, February 12th, Soleil Boughton sold 22,839 shares of Hims & Hers Health stock. The stock was sold at an average price of $10.03, for a total transaction of $229,075.17.

Hims & Hers Health Trading Down 2.4 %

NYSE:HIMS traded down $0.31 during trading hours on Wednesday, hitting $12.38. The stock had a trading volume of 3,891,401 shares, compared to its average volume of 4,713,790. Hims & Hers Health, Inc. has a 1-year low of $5.65 and a 1-year high of $17.16. The business has a 50 day simple moving average of $13.36 and a two-hundred day simple moving average of $9.77. The company has a market cap of $2.65 billion, a PE ratio of -112.82 and a beta of 0.91.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last released its quarterly earnings data on Monday, February 26th. The company reported $0.01 EPS for the quarter, topping analysts' consensus estimates of ($0.02) by $0.03. The firm had revenue of $246.60 million during the quarter, compared to the consensus estimate of $245.84 million. Hims & Hers Health had a negative net margin of 2.70% and a negative return on equity of 7.21%. The firm's revenue was up 47.4% on a year-over-year basis. During the same quarter in the previous year, the company posted ($0.05) earnings per share. Research analysts expect that Hims & Hers Health, Inc. will post 0.1 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research firms have issued reports on HIMS. Leerink Partnrs reaffirmed a "market perform" rating on shares of Hims & Hers Health in a research note on Monday, February 26th. Imperial Capital raised shares of Hims & Hers Health from an "in-line" rating to an "outperform" rating and set a $16.00 price target on the stock in a research note on Wednesday, February 28th. SVB Leerink began coverage on shares of Hims & Hers Health in a research note on Monday, February 26th. They set a "market perform" rating and a $10.00 price target on the stock. Guggenheim raised their price target on shares of Hims & Hers Health from $15.00 to $17.00 and gave the stock a "buy" rating in a research note on Tuesday, February 27th. Finally, Tigress Financial increased their price objective on shares of Hims & Hers Health from $14.00 to $15.00 and gave the stock a "buy" rating in a report on Friday, January 5th. Five investment analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $14.85.

Hedge Funds Weigh In On Hims & Hers Health

A number of hedge funds have recently added to or reduced their stakes in HIMS. Forerunner Ventures Management LLC acquired a new position in Hims & Hers Health in the fourth quarter worth $86,836,000. Marshall Wace LLP lifted its stake in Hims & Hers Health by 99.4% in the fourth quarter. Marshall Wace LLP now owns 4,487,038 shares of the company's stock valued at $28,762,000 after buying an additional 2,236,609 shares during the last quarter. Millennium Management LLC lifted its stake in Hims & Hers Health by 145.8% in the fourth quarter. Millennium Management LLC now owns 3,524,750 shares of the company's stock valued at $22,594,000 after buying an additional 2,090,833 shares during the last quarter. Samlyn Capital LLC bought a new stake in Hims & Hers Health in the first quarter valued at $17,391,000. Finally, State Street Corp lifted its stake in Hims & Hers Health by 147.8% in the second quarter. State Street Corp now owns 2,597,684 shares of the company's stock valued at $11,768,000 after buying an additional 1,549,546 shares during the last quarter. Institutional investors and hedge funds own 63.52% of the company's stock.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.